This is primarily due to the requirement to complete extensive phase three trials, projected to continue until 2025
Because these changes cause no symptoms and rarely show up on standard bloodwork, they often go undetected until real damage has been done
Research Characteristics: Triple-action peptide analogue targeting GLP-1, GIP, and glucagon receptor pathways Studied for effects on receptor binding, signaling, and endocrine regulation Examined in laboratory research for its role in energy balance and multi-pathway modulation THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only
Heres more about why we made the change
Quick tip: If your question is about trial participation, start with the sponsor or ClinicalTrials.gov rather than product ordering information
It is likely to mean a sharp uptake in users